Related Experiment Video
Updated: Jun 19, 2026

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
Do Circulating miRNAs Exhibit Distinct Patterns in Coronary Artery Disease Patients?
Chitra M Mestry1, Minal U Paradkar2, Nitin Shukla3
1Research Laboratories, P. D. Hinduja Hospital & Medical Research Centre, Mahim, Mumbai, India.
Insights
This study identified twelve dysregulated circulating microRNAs (miRNAs) in Indian coronary artery disease (CAD) patients. These miRNAs show potential as novel diagnostic biomarkers for early CAD detection.
Area of Science:
- Genomics
- Molecular Biology
- Biomarker Discovery
Background:
- Coronary artery disease (CAD) is a major global health concern.
- Early diagnosis and understanding molecular mechanisms are crucial for managing CAD.
- Circulating microRNAs (miRNAs) are stable, non-invasive biomarkers involved in disease processes.
Purpose of the Study:
- To identify differentially expressed miRNAs in the plasma of Indian CAD patients using next-generation sequencing.
- To evaluate the potential of these miRNAs as diagnostic biomarkers for CAD.
Main Methods:
- Small RNA sequencing of plasma from 30 CAD patients and 30 controls.
- Differential expression analysis using DESeq2.
- Target gene prediction and functional enrichment analysis.
Main Results:
- Twelve significantly dysregulated circulating miRNAs were identified in CAD patients.
- Novel associations with CAD were found for miR-6806-3p, miR-3614-5p, miR-548e-3p, miR-147b-3p, and let-7d-3p.
- miR-125a-3p, miR-495-3p, and miR-143-3p were implicated in CAD pathogenesis pathways.
Conclusions:
- This is the first comprehensive NGS analysis of circulating small RNAs in Indian CAD patients.
- The identified miRNAs play intricate roles in CAD pathogenesis by targeting key genes.
- These miRNAs show potential as diagnostic biomarkers, requiring further validation in larger cohorts.
Introduction:
Coronary artery disease (CAD) remains a leading cause of morbidity and mortality worldwide. Identifying reliable biomarkers for early diagnosis and understanding the underlying molecular mechanisms are critical for improving patient outcomes. Circulating microRNAs (miRNAs) have emerged as promising non-invasive biomarkers due to their stability in blood and involvement in various pathophysiological processes. This pilot case-control study aims to perform small RNA sequencing using next-generation sequencing in the plasma of Indian CAD patients to identify differentially expressed miRNAs and evaluate their potential as biomarkers.
Methods:
Plasma samples were collected from 30 angiographically verified CAD patients and 30 age-and gender-matched controls with normal coronary arteries. Small RNA libraries were prepared and sequenced using Illumina's NextSeq 2000. Differentially expressed miRNAs were identified using the DESeq2 package, followed by target gene prediction using the miRDB, TargetScan, and miRTarBase databases. Functional enrichment analysis was performed using DAVID.
Results:
Twelve significantly dysregulated circulating miRNAs were identified in CAD patients. miR-6806-3p, miR-3614-5p, miR-548e-3p, miR-147b-3p, and let-7d-3p demonstrated novel associations with CAD, whereas miR-125a-3p, miR-495-3p, and miR-143-3p were highlighted for their significant roles in regulating key molecular pathways implicated in CAD pathogenesis.
Discussion:
This study represents the first comprehensive NGS-based analysis of small RNAs in the plasma of Indian CAD patients. The twelve identified circulating miRNAs highlight their intricate roles in CAD pathogenesis by targeting key target genes involved in critical biological pathways.
Conclusion:
The identified miRNAs highlight their potential as diagnostic biomarkers; however, validation in larger and more diverse cohorts is required to confirm their clinical utility.
Related Concept Videos
Coronary Artery Disease II: Pathophysiology
MicroRNAs
MicroRNAs
MicroRNAs
Coronary Artery Disease I: Introduction
Coronary Artery Disease III: Clinical Manifestations
